Hospital admission (exacerbation) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in hospital admission (exacerbation) compared with long‐acting beta2‐agonist alone (low certainty).
1 finding from 1 review
Mortality (all cause) · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in mortality (all cause) compared with long‐acting beta2‐agonist alone (low certainty).
1 finding from 1 review
Change in baseline trough FEV1 · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
1 finding from 1 review
Change in quality of life · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life SGRQ responder analysis at 6 months · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium probably leads to higher quality of life SGRQ responder analysis at 6 months compared with long‐acting beta2‐agonist alone (moderate certainty).
1 finding from 1 review
Hospital admissions · addition to tiotropium versus either tiotropium or LABA alone for chronic obstructive pulmonary disease
Long‐acting beta2‐agonist plus tiotropium showed no clear difference in hospital admission (all cause) compared with long‐acting beta2‐agonist alone (moderate certainty).
1 finding from 1 review
Exacerbations (OCS) · adults with asthma not well controlled on ICS
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in exacerbations (OCS) compared with long‐acting beta2‐agonists (LABA) add‐on (low certainty).
1 finding from 1 review
AQLQ total 1 = severely impaired; 7 = not impaired at all 22 weeks · adults with asthma not well controlled on ICS
1 finding from 1 review
Serious adverse events 22 weeks · adults with asthma not well controlled on ICS
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in serious adverse events 22 weeks compared with long‐acting beta2‐agonists (LABA) add‐on (low certainty).
1 finding from 1 review
Hospital admission (exacerbation) · adults with asthma not well controlled on ICS
It is very uncertain whether long‐acting muscarinic antagonists (LAMA) add‐on changes exacerbations (hospital) compared with long‐acting beta2‐agonists (LABA) add‐on (very low certainty).
1 finding from 1 review
FEV1 · adults with asthma not well controlled on ICS
1 finding from 1 review
ACQ score Scale = 0 to 6 (0 = no impairment; 6 = maximum impairment) · adults with asthma not well controlled on ICS
1 finding from 1 review
Adverse events (all) · adults with asthma not well controlled on ICS
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in adverse events (all) compared with long‐acting beta2‐agonists (LABA) add‐on (moderate certainty).
1 finding from 1 review
Outcomes · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life St George's Respiratory Questionnaire (SGRQ) score · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in quality of life1 St George's Respiratory Questionnaire (SGRQ); lower… compared with placebo (moderate certainty).
1 finding from 1 review
Severe exacerbations requiring hospitalisation over the study period · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists probably leads to lower severe exacerbations (hospitalisations) compared with placebo (moderate certainty).
1 finding from 1 review
Moderate exacerbations (course of antibiotics or oral steroids) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists probably leads to lower moderate exacerbations (course of antibiotics or oral steroids) compared with placebo (moderate certainty).
1 finding from 1 review
Moderate‐to‐severe exacerbations (rate) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in severe/moderate exacerbations (hospitalisation or course of… compared with placebo (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in mortality (all‐cause) compared with placebo (moderate certainty).
1 finding from 1 review
Participants with one or more serious adverse event (non‐fatal) · patients with chronic obstructive pulmonary disease
Long‐acting beta2‐agonists showed no clear difference in participants with one or more serious adverse event (non‐fatal) compared with placebo (moderate certainty).
1 finding from 1 review